We work with families and patient organisations to ensure our programmes deliver the best treatments for patients.


NovalGen is focused on bispecific antibody treatments and has developed a bispecific antibody T cell engager treatment that provides a potentially efficacious yet more straightforward and less invasive treatment approach than CAR-T cells which require ex vivo manipulation and T cell engineering

Read more

Patient organisations

Find resources and information to help you 

Find out more

Clinical trials

NovalGen is committed to developing innovative treatments. We operate with integrity and carefully test our new treatments in well-designed clinical trials to ensure safety and efficacy.

Read more

About disease areas

Unmet Need in chronic lymphocytic leukemia and mantle cell lymphoma

Read more